

ARC Trinova has acquired Covance's site in Alnwick to form International Contract Research and Development Business

Alnwick, 10 February 2016

Covance Inc. (<http://covance.com/>) has completed the divestment of its Alnwick site in Northumberland, United Kingdom to ARC Trinova, a new company formed by Shott Trinova LLP.

The Alnwick site - with Sanofi heritage - provides CMC & Synthetic Chemistry, Bioanalysis, Drug Metabolism & Pharmacokinetics (DMPK) and Safety Assessment services for pharmaceuticals development. ARC Trinova will add capability in Active Pharmaceutical Ingredient (API) process development and scale up to the multi-kilogram level.

The new business will continue to offer these services to Covance while also seeking to build a large international client base. The company will aim to deliver best in class technology in the fields of contract research, development and small scale manufacturing to maximise effectiveness whilst minimising risk and overall cost. ARC Trinova has a long term vision to grow a large and sustainable business offering this broad array of services to customers all over the world.

"The agreement with ARC Trinova provides a future for the Alnwick site and many of its staff and allows us to collaborate with ARC Trinova in certain areas linked to work performed at other Covance sites," says Steve Street, General Manager and Global Vice President Early Development. He adds "The non-clinical business remains a key component of drug development within Covance."

Managing Director Ian Shott commented: "The Company considers the Alnwick site to be a large very well equipped facility that is perfectly designed to accommodate the full range of capabilities envisaged, with a staff of the highest calibre providing a strong internationally competitive platform for sustainable growth in the future".

About Arc Trinova

Arc Trinova is a Contract Research, Development and Manufacturing Organisation (CRDO) providing the pharmaceutical industry with comprehensive services from drug R&D through small scale manufacture. Arc Trinova will trade under a new brand ArcInova.

Arclnova is focused on providing services linked to the pre-clinical to Phase I/IIa clinical development of new small molecules drug candidates, Process Development, Scale-Up and Manufacturing, covering drug candidates in Development and launched to the Market, at relatively small quantities.

TransAct Advisory Services acted as exclusive M&A advisor on behalf of Covance Inc. in a structured process aimed to consolidate its European site network.

TransAct Advisory Services GmbH & Co. KG
Unter den Linden 16
D-10117 Berlin Germany

Tel.: +49-30-6098989-70
Fax.: +49-30-6098989-79

email: info@transactadvisory.com

www.transactadvisory.com